Last reviewed · How we verify
NCT05176873
A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics of DZD8586 in Healthy Adult Participants
Phase 1 trial testing DZD8586 in Lymphoma, Non-Hodgkin in 64 participants. Completed in 22 May 2022.
11 May 2022
Quick facts
| Lead sponsor | Dizal (Jiangsu) Pharmaceutical Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 64 |
| Start date | 9 December 2021 |
| Primary completion | 11 May 2022 |
| Estimated completion | 22 May 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- DZD8586 — full drug profile →
- Placebo
Conditions studied
- Lymphoma, Non-Hodgkin — all drugs for Lymphoma, Non-Hodgkin →
Sponsor
Dizal (Jiangsu) Pharmaceutical Co., Ltd. — full company profile →
Who can join
Adults 18 to 55, any sex, with Lymphoma, Non-Hodgkin. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a study in healthy adult participants. This is the first time this drug has ever been tested in human, and so it will help to understand what type of side effects may occur with this intervention. It will also measure the levels of drug in the body.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05176873
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of DZD8586
Trials testing the same drug.
- NCT05824585 — DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · Phase 1 · recruiting
- NCT05844956 — A Study of DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (TAI-SHAN1) · Phase 1, PHASE2 · completed
Other recruiting trials for Lymphoma, Non-Hodgkin
Currently open trials in the same condition.
- NCT07308132 — A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies · Phase 1 · recruiting
- NCT06923397 — Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemother · NA · recruiting
- NCT06660563 — A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell No · Phase 1 · active not recruiting
- NCT06343311 — T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) · Phase 1, PHASE2 · recruiting
- NCT06470438 — A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma · Phase 1 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05176873 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dizal (Jiangsu) Pharmaceutical Co., Ltd.
- Last refreshed: 7 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05176873.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing